Message #54 From:
NewsBot Date: February 27, 2007 04:00:00 AM
DEPO News Depomed to Present at the Oppenheimer Pain Management Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) today announced that chairman, president and chief executive officer, John W. Fara, Ph.D., will present on Tuesday, March 6, 2007 at 11:45 a.m. Eastern Time at the Oppenheimer Pain Management Conference taking place in New York.
Interested parties can access a live, or archived, Internet broadcast of the presentation at http://www.wsw.com/webcast/opp/depo. The presentation will be archived for at least two weeks following the presentation.
About Depomed, Inc.
Depomed, Inc. is a specialty pharmaceutical company utilizing its innovative AcuForm™ drug delivery technology to develop novel oral products and improved, extended release formulations of existing oral drugs. AcuForm-based products are designed to provide once daily administration and reduced side effects, improving patient convenience, compliance and pharmacokinetic profiles. ProQuin® XR (ciprofloxacin hydrochloride) extended-release tablets have been approved by the FDA for the once daily treatment of uncomplicated urinary tract infections and are currently being marketed in the United States. In addition, once daily Glumetza™ (metformin hydrochloride extended release tablets) has been approved for use in adults with type 2 diabetes and is currently being marketed in the United States and Canada. The company is conducting a Phase 3 trial in postherpetic neuralgia and has completed a Phase 2 trial in diabetic peripheral neuropathy with its product candidate, Gabapentin GR™. Additional information about Depomed may be found at its web site, www.depomedinc.com.
